ALK-Abelló Earnings Call Transcripts
Fiscal Year 2026
-
Quarterly growth was led by tablets, with pediatric launches, new markets and Europe supporting momentum. Pipeline priorities include peanut AIT Phase III and neffy, while disciplined BD and Germany rebate mitigation remain in focus.
-
Q3 revenue grew 15% in local currencies, led by tablets, while 9M EBIT margin held at 28%. FY guidance was reaffirmed, with growth investment, China trial progress and expanded tablet capacity supporting the outlook.
-
Double-digit sales growth continued in Q2, led by tablets and anaphylaxis products, with revenue up 18% and EBIT up 19%. Guidance was raised, with strong momentum in Europe and ongoing investments in R&D and launches. German rebate changes in 2027 are being proactively managed.
-
Q1 saw revenue and EBIT exceed guidance, driven by strong tablet and anaphylaxis sales, especially in Europe and North America. Upgraded full-year outlook reflects continued momentum, with significant investments in growth and R&D, and key advances in peanut allergy and neffy.
-
Strong revenue and profit growth in 2025 enabled a resumed dividend and continued investment in R&D, production, and sustainability. All board proposals, including an updated remuneration policy and board re-elections, were approved. Shareholders discussed production, AI, and market expansion.
Fiscal Year 2025
-
Strong 2025 results with 15% revenue growth, 26% EBIT margin, and robust expansion in tablets and anaphylaxis products. 2026 guidance targets 11–15% revenue growth, continued double-digit tablet and anaphylaxis sales, and ongoing investment in R&D and infrastructure.
-
Q3 delivered double-digit revenue and EBIT growth, driven by strong pediatric tablet launches, new partnerships, and robust performance across all regions and product lines. The full-year outlook was raised, with continued investment in growth initiatives and a strong balance sheet.
-
Q2 delivered strong revenue and EBIT growth, driven by pediatric tablet launches and adrenaline auto-injectors, prompting an upgraded full-year outlook. Europe and North America led segment growth, with new product rollouts and strategic partnerships supporting momentum.
-
The company targets over 10% annual growth and a 25% EBIT margin by 2025, driven by expanding its allergy tablet portfolio, especially with new pediatric indications and strong European sales. Strategic partnerships, new product launches like Nefy, and a robust pipeline in food allergy and anaphylaxis support long-term growth.
-
Q1 revenue rose 12% to DKK 1.5 billion, led by 22% tablet sales growth and strong pediatric uptake. EBIT margin improved to 31%, and guidance for 2025 remains confident with 9–13% revenue growth expected. Neffy and pediatric launches are set to drive further expansion.
-
Strong financial growth in 2024 was driven by tablet sales and strategic execution, with a focus on reinvestment over dividends. The board and auditor were re-elected, and the Allergy Plus strategy aims for continued expansion and sustainability.
Fiscal Year 2024
-
Revenue grew 15% year-over-year, driven by strong European tablet sales and strategic execution, with EBIT up 65% and margin expansion. 2025 guidance projects 9%-13% revenue growth and a 25% EBIT margin, with Neffy and pediatric launches as key drivers.
-
Q3 delivered 18% organic revenue growth and a 10-point EBIT margin increase, driven by strong tablet sales and cost efficiencies. The outlook remains robust, with new product launches and the Neffy in-licensing deal expected to fuel future growth.
-
Secured exclusive rights to Neffy, a needle-free adrenaline nasal spray, targeting major growth in the anaphylaxis market, with launches in Europe and Canada from 2025. The deal is expected to be earnings-accretive within a few years and supports long-term strategic and financial goals.
-
Q2 saw 21% organic revenue growth, led by strong tablet sales in Europe, driving upgrades to full-year revenue and EBIT margin guidance. The Allergy+ strategy is progressing, with regulatory advances for pediatric tablets and ongoing cost optimization supporting long-term growth.
-
The updated strategy targets doubling treated patients by 2030, expanding into food allergy and anaphylaxis, and maintaining AIT leadership. Financial goals include 10%+ annual sales growth and a 25% EBIT margin, supported by disciplined capital allocation, pipeline expansion, and operational efficiency.